Panax notoginseng in treatment of myocardial ischemia/reperfusion injury and its application prospect
10.3969/j.issn.1001-1978.2015.10.003
- VernacularTitle:中药三七对缺血/再灌注损伤的保护作用及应用前景
- Author:
Guang LI
;
Xiaoyan XING
;
Meishuang ZHANG
;
Jinjin SHI
;
Xuehong DENG
;
Guibo SUN
;
Xiaobo SUN
- Publication Type:Journal Article
- Keywords:
Panax notoginseng;
Panax notoginseng saponins;
myocardial ischemia/reperfusion injury;
calcium overload;
apop-tosis;
inflammation;
VEGF;
ER
- From:
Chinese Pharmacological Bulletin
2015;(10):1340-1344
- CountryChina
- Language:Chinese
-
Abstract:
Myocardial ischemia/reperfusion injury ( MI/RI) is a pathophysiological phenomenon commonly seen during thromboly-sis, percutaneous transluminal coronary angioplasty ( PTCA ) , and coronary artery bypass grafting ( CABG ) . It is defined as restoration of blood flow to a previously ischemic region followed by complex pathological events leading to tissue injury greater than the original ischemic insult. Many experimental interven-tions have been reported to protect the ischemic myocardium in experimental animals; however, with the exception of early reperfusion, none has been translated into clinical practice. The root of Panax notoginseng ( Burk. ) F. H. Chen ( PN) is one of the iconic herbs in traditional Chinese medicine. Traditional pharmacopeia recommended it among the most efficacious herbs for‘promoting blood circulation ’ and hemostasis. Inspired by this, in the last decade, a large number of modern investigators made substantial efforts to search the PN activities against a vari-ety of MIRI. The systematic review was performed according to the protecting drug of the MIRI development guidelines.
